Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Magnetic imaging agent
Patent
1993-12-17
1996-10-08
Hollinden, Gary E.
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Magnetic imaging agent
514492, 514502, 514836, 436173, 534 16, 556 50, 556 63, 556107, 556117, 556134, 556148, A61B 5055
Patent
active
055628940
ABSTRACT:
The present invention relates to the preparation of amino-acyl-type and catecholamine-type compounds having multiple carboxylic acid functional groups. Paramagnetic metal (II) or (III) ion chelate complexes are formed using these compounds for use as intravenous contrast agents to produce enhanced contrast magnetic resonance images of the heart, liver, biliary tree or upper small intestine. The mono- and di-amino acids, their esters and amides, and catecholamine-like derivatives, of EDTA, DTPA, and the like are prepared. The paramagnetic metal (II) or (III) ion complexes are formed and produce T1-related contrast effects in MR images. The compounds and complexes also appear to have low toxicities and to be relatively rapidly and completely cleared from the tissue of a living mammal, e.g. a human being.
REFERENCES:
patent: 2394230 (1946-02-01), Billman
patent: 3859337 (1975-01-01), Herz et al.
patent: 4352751 (1982-10-01), Wieder et al.
patent: 4426453 (1984-01-01), Cree et al.
patent: 4637929 (1987-01-01), Quay et al.
patent: 4647447 (1987-03-01), Gries et al.
patent: 4687659 (1987-08-01), Quay et al.
patent: 4826673 (1989-05-01), Dean et al.
patent: 4859451 (1989-08-01), Quay et al.
patent: 4863716 (1989-09-01), Quay et al.
patent: 4863717 (1989-09-01), Keana
patent: 4880008 (1989-11-01), Lauffer et al.
patent: 4889931 (1989-12-01), Rocklage et al.
patent: 4899755 (1990-02-01), Lauffer et al.
patent: 4909257 (1990-03-01), Engelstad et al.
patent: 4946136 (1990-08-01), Fishlock-Lomax
patent: 4957939 (1990-09-01), Gries et al.
patent: 4972837 (1990-11-01), Engelstad et al.
patent: 4999445 (1991-03-01), White et al.
patent: 5011925 (1991-04-01), Rajagopalan et al.
patent: 5021236 (1991-06-01), Gries et al.
patent: 5039512 (1991-08-01), Kraft et al.
patent: 5057302 (1991-10-01), Johnson et al.
patent: 5077037 (1991-12-01), Wallace
patent: 5094950 (1992-03-01), Kondo et al.
patent: 5135737 (1992-08-01), Keana
patent: 5137711 (1992-08-01), Weber et al.
patent: 5138040 (1992-08-01), Moore et al.
patent: 5274076 (1993-12-01), Barbet et al.
patent: 5312617 (1994-05-01), Unger et al.
patent: 5318771 (1994-06-01), Lauffer et al.
patent: 5399340 (1995-03-01), Raduchel
patent: 5419894 (1995-05-01), Gries et al.
Janoki, G. Y. A. et al., "[.sup.67 Ga]Desferrioxamine-HSA: Synthesis of chelon protein conjugates using cabodiimide as a coupling agent" Int. J. Radiat. Isot. (1983) 34(6):871-877.
Rodgers, S. J., et al., "Ferric ion sequestering agents. 11. Synthesis and kinetics of iron removal from transferrin of catecholyl derivatives of desferrioxamine B.sup.1 " J. Med. Chem. (1983) 26:439-442.
Lempers et al., "A new trinuclear complex of platinum and iron efficiently promotes cleavage of plasmid DNA" Nucl. Acids Res. (1993) 21(8): 1983-1990.
Virzi et al., "New Indium-111 labeled biotin derivatives for improved immunotargeting" Nucl. Med. Biol. (1991) 18(7):719-726.
Bulman, R. A., et al., "Investigations into Techniques for Removing Intracellular Plutonium-l. Complexing Agents Bound to Macromolecules", Health Physics, vol. 40 (1981), pp. 228-231.
Gmelin, L., (1980) Gmelin Handbuch der Anorganischen Chemie, 8th Edition, Springer-Verlag, New York, New York, pp. 1-255.
Keana, J. F. W., et al., "Novel Nitroxides for Spin-Labeling, Trapping, and Magnetic Resonance Imaging Applications", Pure and Applied Chem., vol. 62:2 (1990) pp. 201-205.
Le Doussal, J. M., et al., "In Vitro and In Vivo Targeting of Radiolabeled Monovalent and Divalent Haptens with Dual specificity Monoclonal Antibody Conjugates: Enhanced Divalent Hapten Affinity for Cell-Bound Antibody Conjugate", J. Nuclear Medicine, vol. 30 (1989), pp 1358-1366.
Motekaitis, R. J., et al., "New Multidentate Ligands. X. Chelating tendencies of N", N", N"', N"'-tetraacetic Acid and Ethylenediamine-N-N'-di(acetylglycine)-N,N'-diacetic Acid", J. Am. Chem. Soc., vol. 92 (1970), pp. 423-4230.
Hoener, B-A., et al., "Hepatic Transport of the Magnetic Resonance Imaging Contrast Agent Fe(III)-N-(3-Phenylglutaryl)desferrioxamine B" Mag. Res. Med. (1991) vol. 17, pp. 509-515.
Hoener, B-A., et al., "Comparisons of Fe-HBED and Fe-EHPG as Hepatobiliary MR Contrast Agents" J. Mag. Res. Imag. (1991) 1(3):357-362.
Stark, D. D., et al., "Clinical Application of Gadolinium-DTPA" Nucl. Res. Imag. (1988) C. V. Mosby Company, Chapter 10, pp. 182-200.
Houghten, R. P., et al., "Synthesis of Bis(imides) and Bis(half amides) of NN'-Ethylenebis(iminodi-acetic Acid)" J. Chem. Soc. Perkin Trans. 1 (1982) 11:2693-2696.
Bakker, W. H., et al., "[.sup.111 IN-DTPA-D-Phe.sup.1 ]-Octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation" Life Sciences (1991) 49(22):1583-1591.
Hollinden Gary E.
Regents of the University of California
LandOfFree
Amino-acyl-type and catecholamine-type contrast agents for MRI does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amino-acyl-type and catecholamine-type contrast agents for MRI, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amino-acyl-type and catecholamine-type contrast agents for MRI will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-55389